Our findings suggest that late-onset GBM patients have a poorer prognosis, marked by negative biomarkers like TERT promoter mutations, chromosome 7 gain, and chromosome 10 loss, though they exhibit higher MGMT methylation frequencies, indicating a greater likelihood of benefiting from temozolomide chemotherapy, while early-onset GBM patients show higher BRAF mutation frequencies, indicating a greater potential response to BRAF inhibitors. This evidence concerns the gene MGMT and glioblastoma.